NONPOROUS PERFLUOROMEMBRANES FOR WOUND DRESSINGS
Small Business Information
814 1ST STATE BLVD, Wilmington, DE, 19804
PLIMMER, PETER N
AbstractOsteoporosis is a major worldwide public health problem with over 20 million individuals affected in the united states. Over 1.5 million fractures occur in the united states annually, resulting in 750,000 visits to the physician and long term hospitalization with a total impact to the health care system in excess of billion dollars. The current state-of-the-art in clinical diagnosis for Osteoporosis is bone density measurements which can be use neither to predict the onset of disease nor monitor the shot term effectiveness of therapy. At present, the only clinically useful diagnostic tolls for this purpose are microtitre plate immunoassays which are cumbersome to use and are available only in large clinical laboratories. Eyre and colleagues have identified and characterized the N- telopeptide cross-linking domain of type I collagen (NTx) as a highly specific marker for bone resorption. A microtitre plate immunoassay for this analyte has been commercialized by Ostex International, Inc., of Seattle, WA, and approved by the FDA. Metrika laboratories will develop the Digital Response NTx test which is a single-use, disposable, bone resorption assay based on the simultaneous measurement of the NTx bone specific marker and creatinine to yield a normalized quantitative result. The test device, which will be about the size of a credit card, will combine inexpensive microelectronics and dry reagent immunochemistry. This innovative test will be extremely simple to operate and will provide a digital display of results in a few minutes. The technology of Digital Response will benefit patients by providing a convenient and inexpensive method to monitor, at the point-of-care, the effectiveness of treatment to reduce accelerated bone loss in postmenopausal women. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 105 --PROJECT NUMBER......1 R43 AR44146-01A1 INVESTIGATOR NAME/ADDRESS FY 97 SCHULDIES, JOHN J IRG/INTRAMURAL UNIT..ZRG4 INDUSTRIALL CERAMIC TECH INC AWARD AMOUNT......... $99,786 37 ENTERPRISE DR ANN ARBOR, MI 48103 PERFORMING ORGANIZATION: INDUSTRIAL CERAMIC TECHNOLOGY, INC. TITLE CERAMIC COMPOSITE RESEARCH FOR TOTAL JOINT ARTHROPLASTY NO ABSTRACT ON FILE $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 106 --PROJECT NUMBER......2 R44 AR44166-02 INVESTIGATOR NAME/ADDRESS FY 97 ANDREWS, STEFFEN IRG/INTRAMURAL UNIT..ZRG2 RVISION CORPORATON AWARD AMOUNT......... $503,758 190 EAST 9TH AVENUE STE 228 DENVER, CO 80203 PERFORMING ORGANIZATION: RVISION CORPORATION TITLE MULTIMEDIA EDUCATION FOR JOINT REPLACEMENT PATIENTS ABSTRACT: In Phase I of this SBIR research project, Revision demonstrated the ability to design, film, produce and pilot study the effectiveness of customized education and exercise videotapes for total hip arthroplasty (THA) patients. A library of 41 exercise and education segments narrated in both English and Spanish was built along with software to allow physicians to customize tapes for each patient's needs. In a pilot study, the customized types were evaluated with 19 THA patients. The study found tape patients had greater understanding or pre-op home preparation strategies, exercised more frequently, and had a shorter average length of hospital stay. Although the sample size is too small for generizability, the trend is encouraging and worthy of further study. In Phase II, Rvision will produce a comprehensive library of customizable video exercise and education segments for both THA and TKA (knee) patients. Additional refinements will be made to the software used for previewing segments and customization of tapes to the physicians' prescriptions. Phase II will conclude with a randomized trial of 500 TA ad TKA patients to assess the effectiveness of the customized tapes. Outcome variables include compliance with the exercise prescription, time to functionality, and cost of care.
* information listed above is at the time of submission.